AUTHORS
Sacha Benaoudia, PhD, Anja Barbour2, Tina Nguyen3, Andrea Poletti, PhD4, Noemie Leblay, PhD5, Mansour Poorebrahim, PhD6, David Jung7, Sungwoo Ahn, PhD8, Takeshi Yoroidaka, MD, PhD9, Sae Matsuoka10, Holly Lee, MD, PhD11, Mehdi Arbabi-Ghahroudi12, Paola Neri, MD, PhD13, Scott McComb14, Nizar Bahlis, MD15
AFFILIATIONS
1 University of Calgary, Calgary, Alberta, Canada
2 University of Calgary, Calgary, Alberta, Canada
3 NRC, Ottawa, Canada
4 University of Calgary, Calgary, Alberta, Canada
5 University of Calgary, Calgary, Canada
6 University of Calgary, Calgary, Alberta, Canada
7 University of Calgary, Calgary, Alberta, Canada
8 University of Calgary, Calgary, Alberta, Canada
9 University of Calgary, Calgary, Alberta, Canada
10 University of Calgary, Calgary, Alberta, Canada
11 University of Calgary, Calgary, Alberta, Canada
12 NRC, Ottawa, Canada
13 University of Calgary, Calgary, Alberta, Canada
14 NRC, Ottawa, Canada
15 University of Calgary, Calgary, Alberta, Canada
ABSTRACT
BACKGROUND
CD19- and BCMA-targeted cell therapies have profoundly transformed the clinical management of patients with hematological malignancies. However, relapses remain common, and effective such therapies are still unavailable for many hematological cancers. To identify novel therapeutic targets, we analyzed both public and in-house transcriptomic datasets and identified CD180 as a promising target antigen candidate for hematological malignancies, including multiple myeloma (MM), acute myeloid leukemia (AML), and lymphoma. Importantly, its low expression profile across healthy tissues suggests that CD180 may represent a suitable target for chimeric antigen receptor (CAR) T-cell therapy.
METHODS
Llamas were immunized with human CD180, and single-domain antibodies were subsequently isolated and screened for their binding affinity to CD180. Three candidates were selected and cloned into chimeric antigen receptor (CAR) constructs to generate CAR T cells. CD180-targeting CAR T cells were evaluated for cytotoxic activity, expression of activation markers, and cytokine release in vitro. Their antitumor activity was also assessed in vivo in several mouse models.
RESULTS
Three CD180-targeting single-domain antibodies (sdAbs; sd1, sd2, and sd3) were cloned into lentiviral vectors and used to generate the 180sd1, 180sd2, and 180sd3 CAR T cells. CAR surface expression was confirmed by flow cytometry using an anti-VHH antibody. Flow cytometry-based cytotoxicity assays demonstrated potent tumor cell killing (≥80%) by 180sd1, 180sd2, and 180sd3 against two MM cell lines (RPMI 8226 and KMS-12-BM). In addition, 180sd1 and 180sd2 exhibited strong cytotoxic activity (≥70%) against two AML cell lines (AML-2 and MOLM-13) and two Burkitt lymphoma cell lines (RAMOS and RAJI).
To assess target specificity, the CD180-negative cell lines K562 and EJM were exposed to the CD180-targeting CAR T cells. Neither 180sd1 nor 180sd2 induced tumor cell killing, whereas 180sd3 mediated mild tumor cell lysis (20–50%). Following engineered expression of CD180 in K562 and EJM cells, 180sd1 and 180sd2 induced robust cytotoxicity (75–95%), while 180sd3 had similar killing efficacy than in absence of the antigen. These findings demonstrated that the cytotoxic activity of 180sd1 and 180sd2 is highly antigen-dependent, whereas the activity of 180sd3 is consistent with tonic signaling or antigen-independent activation.
We next evaluated cytokine secretion (IL-2 and IFN-γ), activation marker expression (CD25 and CD69), and Granzyme B (GZMB) production. These functional assays corroborated the cytotoxicity data and further highlighted the superior performance of 180sd1 and 180sd2 compared with 180sd3. Consequently, 180sd1 and 180sd2 were selected for in vivo evaluation.
In NSG MHC-I/II knockout mice bearing either intravenous or subcutaneous RPMI 8226 tumors, both 180sd1 and 180sd2 significantly reduced tumor burden and prolonged survival compared with non-transduced T-cell controls. Similarly, in the MOLM-13 AML xenograft model, both CAR T-cell products induced deep and durable antitumor responses and significantly extended survival. Comparable results were obtained in NSG-SGM3 mice engrafted with AML-2 cells, where 180sd1 and 180sd2 produced robust antitumor activity and improved overall survival.
Finally, primary tumor samples from patients with MM and AML were screened for CD180 expression and evaluated in in vitro cytotoxicity assays. Tumor cells expressing CD180 were susceptible to CD180-targeting CAR T-cell-mediated killing, whereas CD180-negative samples showed no detectable cytotoxicity. These findings further demonstrate the antigen-dependent activity of CD180-targeting CAR T cells in primary patient samples.
SUMMARY
Transcriptomic analyses enabled the identification of CD180 as a novel target antigen for CAR T-cell therapy in hematological malignancies. We successfully generated novel CD180-targeting sdAb binders and CAR T cells that demonstrated potent, antigen-specific antitumor activity across multiple hematological cancer cell lines, primary patient samples, and xenograft models. Collectively, these findings support the clinical translation of CD180-targeting CAR T-cell therapy for the treatment of hematological malignancies.
DISCLOSURES
Sacha Benaoudia, PhD: No relevant conflicts of interest to declare.